Roche Pharmaceutical Development and Sales Overview
Lunsumio (mosunetuzumab, CD20 x CD3, RG7828)
Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously
Indication
2L+ FL
Relapsed or refractory FL
Phase/study
# of patients
Design
Phase III
CELESTIMO
N=400
ARM A: Lunsumio plus lenalidomide
ARM B: Rituxan plus lenalidomide
Phase Ib/II
N=118
ARM A: Lunsumio plus tiragolumab
ARM B: Lunsumio plus tiragolumab plus
Tecentriq
Dose escalation phase
Dose expansion phase
Primary endpoint
Status
CT Identifier
Relapsed or refractory CLL
Phase Ib/II
N=56
ā
Lunsumio monotherapy (3L+ CLL)
Progression-free survival
"
Phase lb: Dose-limiting toxicity
FPI Q4 2021
Phase II: Best complete response
FPI Phase lb Q2 2022
Safety, dose-limiting toxicity and RPTD
FPI Q1 2022
NCT04712097
NCT05315713
FL=follicular lymphoma; r/r=relapsed/refractory; RPTD=Recommended Phase II Dose; CLL=Chronic lymphocytic leukemia
Roche
82
42
OncologyView entire presentation